The enrichment of TP53 and PPM1D mutations in t-AML can be explained by preferential selection of pre-existing HSCs, which already harbor TP53 and PPM1D mutations prior to chemotherapy exposure. This evidence concerns the gene PPM1D and acute myeloid leukemia.